Save Product
Product Details
Synonyms
Disintegrin and metalloproteinase domain-containing protein 9 (EC:3.4.24.-) Cellular disintegrin-related protein, Meltrin-gamma, Metalloprotease, disintegrin, cysteine-rich protein 9, Myeloma cell metalloproteinase, ADAM9, KIAA0021, MCMP, MDC9, MLTNG
Source
Mouse ADAM9, His Tag (AD9-M52H3) is expressed from human 293 cells (HEK293). It contains AA Ala 206 - Asp 697 (Accession # Q61072).
Predicted N-terminus: Ala 206
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 55.2 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Supplied as 0.2 μm filtered solution in 25 mM MES, 150 mM NaCl, pH6.0 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Mouse ADAM9, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Mouse ADAM9, His Tag (Cat. No. AD9-M52H3) is more than 95% and the molecular weight of this protein is around 57-72 kDa verified by SEC-MALS.
Report
Bioactivity
Measured by its ability to cleave a fluorogenic peptide substrate Mca-PLAQAV-Dpa-RSSSR-NH2. The specific activity is >3 pmol/min/μg (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Disintegrin and metalloproteinase domain-containing protein 9
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
3 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
